U.S. Medical Equipment Stock News

Indivior Pharmaceuticals stock just shed 6.6% in a single session, yet the latest quarter reads more like a profitability step change than a collapse in confidence. The company printed Q2 basic earnings per share of US$1.02 on revenue of US$343 million, both comfortably above the prior quarter levels. Over the trailing twelve months that has translated into a 26.7% net margin against just 9.2% a year earlier. The market is focusing on the headline price drop. The earnings story is about a...

Olin (OLN) is back in focus after its latest quarterly report showed a net loss, continued operational disruptions at the Freeport VCM plant, and a sharp one day drop in the stock price. See our latest analysis for Olin. At around US$18.62, Olin’s recent one day share price drop of about 16% around the earnings release sits within a wider pattern, with the 90 day share price return down 35.35% while the 1 year total shareholder return is slightly positive at 1.26%. The sharp reaction suggests...

Bandwidth stock has delivered a very strong 223.7% return over the past year, but the valuation checks and current market multiples suggest the shares are not obviously cheap at today’s price of US$43.47. Over the last 12 months, Bandwidth has returned 223.7%, which puts current investors in a position where expectations for future performance are already a big part of the price. The key support for the current valuation can come from Bandwidth’s ability to turn revenue into consistent cash...

Rising inflation, hawkish comments from Federal Reserve officials and uncertainty around the next move on interest rates are reshaping how investors think about banks and insurers. Some stocks could benefit if higher rates support lending margins or investment income, while others may face pressure from funding costs and credit risks. This article focuses on three stocks from our Financial Sector screener that appear closely tied to these rate and policy trends. You will see how each stock is...

Penny stocks often look risky at first glance, especially when headlines swing between stronger manufacturing in parts of Europe and Asia and softer demand or slower activity elsewhere. The Financially Fit Penny Stocks screener focuses on companies trading below 5 that still show solid financial health. That can help you focus on lower risk profiles within this higher risk corner of the market. In this article you will see 3 of the stocks from this screener, with clear reasons why each one...

AES stock is back in focus as a potential takeover and a long term share price decline of 26.1% over five years meet a set of valuation checks that currently lean cheap, including an intrinsic value estimate from a Discounted Cash Flow (DCF) that points to meaningful upside versus the market price. Over the past five years, AES shares have declined 26.1%, which keeps the stock trading well below where longer term holders bought in and puts more weight on whether today’s price offers a margin...

FedEx stock has returned 76.0% over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently lean toward the shares trading below what the fundamentals imply. That sets up an important check for investors on whether the recent gains have simply closed a gap or if the market is still pricing FedEx cautiously. FedEx has gained 76.0% over the past year, which puts the current share price in sharp focus against its underlying earnings power...

In the past quarter ended June 30, 2026, GeneDx Holdings Corp. reported Q2 revenue of US$114.44 million, up from US$102.69 million a year earlier, but swung from net income of US$10.81 million to a net loss of US$17.74 million, with basic and diluted loss per share of US$0.60. Despite reporting a larger six‑month net loss of US$81.06 million versus US$4.28 million previously, GeneDx exceeded consensus expectations with Q2 revenue and earnings, returned to adjusted profitability ahead of...

In July 2026, AtriCure, Inc. reported second-quarter results showing higher revenue of US$153.6 million and a shift from a net loss to net income of US$8.96 million, alongside new full-year 2026 guidance projecting revenue of US$602 million to US$610 million and net income per share of US$0.05 to US$0.13. On the same day, AtriCure also filed two ESOP-related shelf registrations for up to 2,250,000 common shares totaling US$78.84 million, highlighting both improving profitability and plans to...

In the past quarter, Artisan Partners Asset Management Inc. reported second-quarter 2026 revenue of US$307.9 million and net income of US$80.9 million, both higher than a year earlier, alongside basic and diluted earnings per share from continuing operations of US$1.11 versus US$0.94 previously. For the first half of 2026, the firm also lifted revenue to US$610.9 million and net income to US$138.9 million year on year, while declaring a higher quarterly dividend of US$0.80 per share payable...

The market just marked TG Therapeutics down hard, with the stock dropping about 11% the day after earnings, even as the core multiple sclerosis drug story looked stronger on the surface. Investors came in after a solid 12 month run, only to be met with an earnings print that paired powerful BRIUMVI revenue of about US$228 million with a sharp hit to bottom line profit. The headline this quarter is margin pressure. Heavy manufacturing related charges cut reported net income to US$7.8 million...

Ocular Therapeutix stock inched up about 3% to US$8.40 after earnings, a modest move for a biotech that has been drifting lower over the past quarter. The headline is not about a sudden swing into profit. It is about how much revenue growth investors are willing to pay for when the losses remain heavy. Quarterly revenue sat in the low teens in millions of US dollars, while net loss stayed deep in the tens of millions. That mix keeps the spotlight on the long term. For anyone looking at Ocular...

NIO (NIO) just reported July delivery figures that caught market attention, with 35,934 vehicles delivered for the month and 227,057 year to date, alongside the launch of the All-New ES8 Five-Seat Version. See our latest analysis for NIO. NIO’s July delivery update comes after a mixed price stretch, with the share price at US$4.81 and a 7-day share price return of 2.78%, while the 90-day share price return has declined 18.47%. Over a longer horizon, the 1-year total shareholder return of...

Lantheus Holdings stock has delivered very strong returns over the past few years, yet the current price sits close to the agreed cash offer from Curium, which raises questions about how much upside is left in the valuation. Over the past 5 years, Lantheus Holdings has returned about 294.0%, which puts recent share price moves into the context of a very strong multi year run. The agreed Curium acquisition, with a headline value of up to US$8b tied to milestones, can anchor expectations for...

Monster Beverage stock has delivered strong gains over the last few years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiple checks currently point to the shares trading at a premium. After a series of solid operating updates and positive expectations around demand, the question for investors is whether the recent price still leaves enough room for comfort. Monster Beverage has returned 89.4% over the past 5 years, which puts extra focus on whether...

CRH plc recently reported past second-quarter and half-year 2026 results, with revenue rising to US$10,777 million and quarterly net income reaching US$1,486 million, while also reaffirming full-year earnings guidance and lifting its quarterly dividend to US$0.39 per share. Alongside higher earnings, CRH continued its multi-year share repurchase effort, having bought back 82,528,887 shares for about US$5.89 billions since March 2023, underlining management’s focus on shareholder...

Compugen stock barely flinched after earnings, ticking up about 1% to US$2.38, yet the real story sits far beyond today’s modest move. You are looking at a biotech that has just posted another small quarter of revenue at US$2.6m and a quarterly net loss of about US$7m, while still carrying a price tag of only 6.4x trailing earnings. The time horizon is the tension. In the short term, Q2 is about controlled burn and a long cash runway into 2029. Over multiple years, the debate shifts to...

Ryerson Holding Corporation recently reported past second-quarter 2026 results, with sales of US$2.01 billion and net income of US$15.5 million, while also declaring a quarterly cash dividend of US$0.1875 per share payable on September 17, 2026. Alongside this, the company issued third-quarter guidance targeting net income of US$19 million to US$21 million and net sales of US$1.87 billion to US$1.95 billion, offering investors a clearer view of its near-term earnings outlook. With this new...

Snowflake (SNOW) is back in focus after the company rolled out its Cortex AI Gateway, along with new security partnerships with Aembit and 1Password, sharpening attention on how its stock reflects growing interest in enterprise AI. See our latest analysis for Snowflake. Those Cortex AI and security announcements have arrived alongside a sharp shift in sentiment, with Snowflake’s share price up 4.86% in the last day and delivering a 90 day share price return of 120.07%, while the 1 year total...

Lindblad Expeditions Holdings stock jumped almost 12% to $33.12 after the Q2 print, capping a strong run over the past three months. The move reflects how quickly investors rewarded a clearer story around profitability. Q2 revenue came in at about $199.2 million, with adjusted earnings before interest, tax, depreciation and amortization margin at 16.3%, and occupancy at 91% on its expedition sailings. The excitement sits against a tougher backdrop. Lindblad remains loss making on a trailing...

The market gave Costamare Bulkers Holdings a polite nod rather than a standing ovation. The stock was up about 3% to US$20.14 after the report, even though Q2 basic earnings per share of roughly US$0.21 and net income of about US$5.2m keep the story very much in “repair mode” after a loss making stretch over the past year. For a company seen by many as a dry bulk recovery and balance sheet reset story, the real headline is that profitability is back on the page while the share price still...

Sally Beauty Holdings walked into this report priced as a discounted, debt‑laden specialty retailer. The stock had already climbed over the past month, and the real jolt came today with a 7.8% jump to US$16.13 after earnings hit the tape. The headline is simple: profit quality surprised in a business many investors still treat as ex growth. Adjusted earnings per share landed around the mid US$0.50s and trailing twelve month earnings reached just under US$2 per share, while net profit margin...

ExxonMobil Holdings (NYSE:XOM) executives warn that global refining bottlenecks, worsened by conflicts involving Russia and in the Middle East, could keep fuel prices elevated even if crude oil prices soften. Chevron issues similar caution on refining capacity, reinforcing concerns about a prolonged period of higher fuel costs for end consumers. Former President Donald Trump publicly criticizes ExxonMobil for what he describes as excessive wartime profits linked to the current conflict with...

nVent Electric (NYSE:NVT) drew investor attention on July 31, 2026, after reporting second quarter results alongside a new expansion of its data center liquid cooling footprint in Blaine, Minnesota, tied to AI and high-performance computing demand. See our latest analysis for nVent Electric. The recent expansion news arrives alongside strong market interest in nVent Electric, with the 1-day share price return of 3.63% and 7-day share price return of 12.46% contrasting with a softer 90-day...